Press Releases July 27, 2026 07:00 AM

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Harrow to Release Q2 2026 Financial Results and Host Earnings Webcast on August 10-11

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
HROW

Harrow, Inc., a leading provider of ophthalmic disease management solutions in North America, announced it will report its financial results for the second quarter ended June 30, 2026, on August 10 after market close. The company will host a conference call and live webcast on August 11 to discuss the results and business updates.

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
HROW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harrow specializes in ophthalmic disease management, addressing conditions such as dry eye disease, macular degeneration, cataracts, and glaucoma.
  • Financial results for Q2 2026 will be announced after market close on August 10, with a webcast and conference call scheduled for the following day.
  • The company focuses on safe, effective, accessible, and affordable ophthalmic medications to improve patient outcomes.
  • Sectors impacted include healthcare, biotechnology, and pharmaceutical markets, especially those focused on ophthalmology.

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026, to discuss the results and provide a business update.

Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
VP of Investor Relations & Communications
[email protected]
617-913-8890


Risks

  • Potential variability in financial performance could impact investor sentiment and stock price.
  • Ophthalmic drug development and regulatory approval risks may affect future product availability and growth.
  • Market competition and pricing pressures in the healthcare and pharmaceutical sectors remain uncertainties.

More from Press Releases

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call Jul 27, 2026 UPDATE — Commerce Secretary Lutnick, Senior Counselor to President Trump Dr. Navarro, South Carolina Attorney General Wilson to Celebrate Historic 10% Increase in U.S. Aluminum Production Jul 27, 2026 Ilya Sutskever’s Safe Superintelligence Inc. and NVIDIA Announce Long-Term Strategic Partnership Jul 27, 2026 Bridger Aerospace Awarded $58 Million Contract with Texas A&M Forest Service to Build State Wildfire Aviation Surveillance Program Jul 27, 2026 Varonis Heads to Black Hat USA 2026 and DEF CON 34 Jul 27, 2026